-
Research Services<a class="dhimg1" href="/shichangdetail1/9.html" target="_self" rel="nofollow"> <img src="https://omo-oss-image.thefastimg.com/portal-saas/pg2026042316544414203/cms/image/8926ff01-64bc-4928-a995-396bdb9d8102.jpg" alt="Aniphe BioLab"> </a> <a class="dhimg2" href="/shichangdetail/8.html" target="_self" rel="nofollow"> <img src="https://omo-oss-image.thefastimg.com/portal-saas/pg2026042316544414203/cms/image/26342b34-4f1e-4d28-9166-7b685e6d70c3.jpg" alt="Aniphe BioLab"> </a>
-
-
Preclinical CRO<a class="dhimg1" href="/shichangdetail/6.html" target="_self" rel="nofollow"> <img src="https://omo-oss-image.thefastimg.com/portal-saas/pg2026042316544414203/cms/image/cc43bac1-07d9-4340-9677-fbe01c51330a.jpg" alt="Aniphe BioLab"> </a> <a class="dhimg2" href="/shichangdetail/10.html" rel="nofollow" target="_self"> <img src="https://omo-oss-image.thefastimg.com/portal-saas/pg2026042316544414203/cms/image/f1d8f739-0d36-4cb8-adeb-26de791d909c.jpg" alt="Aniphe BioLab"> </a>
-
-
-
-
Publish an article
Irritable Bowel Syndrome
Introduction to IBS Animal Models
Animal models of irritable bowel syndrome (IBS) can be established through stress induction, pharmacological stimulation, and modulation of the gut microbiota. Following model induction, animals exhibit symptoms such as diarrhea, constipation, alternating diarrhea and constipation, intestinal motility disturbances, visceral hypersensitivity, intestinal inflammation, and behavioral abnormalities, thereby accurately replicating the hallmark clinical manifestations and pathological features of IBS.
Advantages of the IBS Animal Model Platform Service at Aniphe BioLab
Our platform boasts a well‑established and versatile animal model for irritable bowel syndrome, capable of meeting diverse research needs, including mechanistic studies, drug screening, and efficacy evaluation.
![]() |
The modeling methods are diverse. Various classic modeling approaches—such as stress induction, pharmacological stimulation, and dysbiosis—are employed to suit different research objectives. |
![]() |
High degree of symptom fidelity It consistently reproduces the typical IBS clinical symptoms, including visceral hypersensitivity, intestinal motility abnormalities, and diarrhea/constipation. |
![]() |
The model exhibits good uniformity. The modeling success rate is high, intra-group variability is low, experimental results are highly reproducible, and the data are reliable. |
![]() |
Standardized feeding management and control Standardized husbandry and condition monitoring throughout the entire study, with compliant experimental procedures and traceable data. |
![]() |
The testing system has been improved. It can perform multi-dimensional assessments, including intestinal pathology, gastrointestinal motility, pain sensitivity, and microbiota analysis. |
![]() |
One-stop service Covering the entire workflow—from model establishment and animal care to sample collection and biomarker analysis—this solution efficiently supports research projects. |
|
The filament occlusion method (MCAO) is used to establish the model, which avoids craniotomy, minimizes animal trauma, and yields highly reproducible results. |
Standardized surgical protocols, combined with an experienced technical team, ensure the stability and consistency of model creation. |
The Longa score and the Bederson score, combined with TTC staining, were used to comprehensively validate the model’s phenotype. |
Retain photographs of key procedural milestones and original records to ensure traceability of the experimental process. |
A standardized in vivo solution that meets the needs of cerebral ischemia mechanism research and drug efficacy evaluation. |
| Modeling cycle | 1–3 weeks |
|
|
Mice and rats of SPF grade |
|
|
Pivobromide and linaclotide are widely used and can improve intestinal motility disorders, alleviate visceral hypersensitivity, and relieve abdominal pain. |
|
|
It is widely used in research on intestinal motility disorders and visceral hypersensitivity mechanisms, studies of brain–gut axis regulation, screening of anti‑abdominal pain and gastrointestinal motility agents, investigations into the gut microbiota and immune modulation, as well as in the pharmacological evaluation of probiotics, natural products, and innovative therapies, thereby providing an essential experimental platform for IBS basic research and new drug development. |
Construction of an IBS Animal Model
01 Restraint stress model: Experimental animals are subjected to periodic limb restraint, and chronic psychological stress is used to induce intestinal dysfunction, resulting in IBS‑typical symptoms such as visceral hypersensitivity and abnormal defecation.
02 Ice-Water Stimulation Model: This model employs cold stimuli, such as immersion in ice water, to stimulate the gastrointestinal tract and induce gastrointestinal motility dysfunction, thereby mimicking irritable bowel syndrome under cold‑induced conditions.
03 Inflammation‑induced IBS model: Mild intestinal inflammation is first induced; following resolution of the inflammation, residual symptoms such as intestinal hypersensitivity and defecation disturbances persist, thereby mimicking IBS triggered by infection.
04 Mechanical Distension–Induced IBS Model: Repeated mechanical distension of the intestinal lumen via an intraluminal balloon induces sensitization of intestinal mechanoreceptors, thereby reliably mimicking the core pathological feature of visceral hypersensitivity.
Model features: Various construction methods are available, allowing for the selection of different modeling approaches depending on the specific research focus. After model construction, the resulting functional disturbances are pronounced and closely resemble clinical symptoms, making these methods widely applicable and ideal for use.
Aniphe BioLab Inc.
Address:
Runcheng, No. 8 Longtai Road, Jiangbei New Area, Nanjing City, Jiangsu Province
Building 8, Science Park
Postal Code: 210007
Phone:025-8520 8061
Email:info@aniphebio.com(Consultation)
Email:order@aniphebio.com(Order)
WeChat Official Account
Video Account

















Positive drug
Application areas
Su Public Security Bureau Internet Information Service Filing No. 32010402001421